Homoharringtonine and granulocyte colony-stimulating factor priming for acute myeloid leukemia: is it ready for prime time?

References

• Chen L, Yin Q, Mi R, et al. CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous Leukemia: a modified combination chemotherapeutic combination. Leuk Lymphoma2013;54:2291–2293.
   PubMed Web of Science ®Google Scholar
• Smith M, Barnett M, Bassan R, et al. Adult Acute Myeloid Leukaemia. Crit Rev Oncol Hematol 2004;50:197–222.
   PubMed Web of Science ®Google Scholar
• Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 1994;83:2086–2092.
   PubMed Web of Science ®Google Scholar
• Vogler WR, McCarley DL, Stagg M, et al. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia 1994;8:1847–1853.
   PubMed Web of Science ®Google Scholar
• Thomas X, Fenaux P, Dombret H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 1999; 13:1214–1220.
   PubMed Web of Science ®Google Scholar
• Karanes C, Kopecky KJ, Head DR, et al. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leuk Res 1999;23:787–794.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004;22:1078–1086.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005;23:4110–4116.
   PubMed Web of Science ®Google Scholar
• Milligan DW, Wheatley K, Littlewood T, et al. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 2006;107:4614–4622.
   PubMed Web of Science ®Google Scholar
• Powell RG, Weisleder D, Smith CR Jr. Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci 1972; 61:1227–1230.
   PubMed Web of Science ®Google Scholar
• O’Dwyer PJ, King SA, Hoth DF, et al. Homoharringtonine–perspectives on an active new natural product. J Clin Oncol 1986; 4:1563–1568.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des 2011;17:59–64.
   PubMed Web of Science ®Google Scholar
• Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J (Engl) 1976;2:263–272.
   Google Scholar
• Grem JL, Cheson BD, King SA, et al. Cephalotaxine esters: antileukemic advance or therapeutic failure?. J Natl Cancer Inst 1988;80:1095–1103.
   PubMed Web of Science ®Google Scholar
• Mai WY, Lin MF. Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells. Chin Med J (Engl) 2005;118:487–492.
   PubMed Web of Science ®Google Scholar
• te Boekhorst PA, Lowenberg B, Sonneveld P. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 1994;8:1480–1486.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743–752.
   PubMed Web of Science ®Google Scholar
• High remission induction (traditional sino-western HOAP) regimen for acute nonlymphocytic leukemia. Chin Med J (Engl) 1980; 93:565–568.
   Google Scholar
• Bian SG, Hao YS, Wang ZC. [Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia]. Zhonghua Nei Ke Za Zhi 1990;29:22–25, 60.
   PubMedGoogle Scholar
• Legha SS, Keating M, Picket S, et al. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 1984;68:1085–1091.
   PubMedGoogle Scholar
• Stewart JA, Krakoff IH. Homoharringtonine: a phase I evaluation. Invest New Drugs 1985;3:279–286.
   PubMed Web of Science ®Google Scholar
• Warrell RP Jr, Coonley CJ, Gee TS. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol 1985;3:617–621.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Seiter KP, Ahmed T, et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 1996;10:40–42.
   PubMed Web of Science ®Google Scholar
• Levy V, Zohar S, Bardin C, et al. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 2006;95:253–259.
   PubMed Web of Science ®Google Scholar
• Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 1992;6:1189–1191.
   PubMed Web of Science ®Google Scholar
• Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997;99:939–944.
   PubMed Web of Science ®Google Scholar
• te Boekhorst PA, Lowenberg B, Vlastuin M, Sonneveld P. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 1993;7:1191–1198.
   PubMed Web of Science ®Google Scholar
• Jin J, Jiang DZ, Mai WY, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 2006;20:1361–1367.
   PubMed Web of Science ®Google Scholar
• Gu LF, Zhang WG, Wang FX, et al. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 2011;137:997–1003.
   PubMed Web of Science ®Google Scholar
• Fang B, Liu Y, Zhou J, et al. Salvage therapy with endostatin, low-dose homoharringtonine, and cytarabine in combination with granulocyte-colony stimulating factor for elderly patients with primary refractory acute myeloid leukemia. Am J Hematol 2012;87:126–127.
   PubMed Web of Science ®Google Scholar
• Mi Y, Xue Y, Yu W, et al. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype. Leuk Lymphoma 2008;49:524–530.
   PubMed Web of Science ®Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075–4083.
   PubMed Web of Science ®Google Scholar
• Allan EK, Holyoake TL, Craig AR, et al. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 2011;25:985–994.
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu Y, Michaels S, et al. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009;23:1446–1454.
   PubMed Web of Science ®Google Scholar